• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

853299-07-7 (K03861)

1

Identification

K03861 K03861
Name K03861
Formula C24H26F3N7O2
MW 501.5041496
CAS No. 853299-07-7
EINECS
Smiles NC1=NC(OC2=CC=C(NC(NC3=CC(C(F)(F)F)=C(CN4CCN(C)CC4)C=C3)=O)C=C2)=CC=N1
Synonyms K 03861, K-03861
InChI InChI=1S/C24H26F3N7O2/c1-33-10-12-34(13-11-33)15-16-2-3-18(14-20(16)24(25,26)27)31-23(35)30-17-4-6-19(7-5-17)36-21-8-9-29-22(28)32-21/h2-9,14H,10-13,15H2,1H3,(H2,28,29,32)(H2,30,31,35)
2

Introduction

K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely.

Background Information

K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely. ......by AdooQ BioScience, LLC
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely. ......by BOC Sciences
AUZ454 is a potent and selective Type II FLT3 inhibitor. AUZ454 is able to override drug resistance that less potent "type I" inhibitors and "type II" first-generation FLT3 inhibitors cannot. Constitutively activated mutant FLT3 has emerged as a promising target for therapy for the subpopulation of acute myeloid leukemia (AML) patients who harbor it. The small molecule inhibitor, PKC412, targets mutant FLT3 and is currently in late-stage clinical trials. However, the identification of PKC412-resistant leukemic blast cells in the bone marrow of AML patients has propelled the development of novel and structurally distinct FLT3 inhibitors that have the potential to override drug resistance and more efficiently prevent disease progression or recurrence. ......by MedKoo Biosciences, Inc.
AUZ454 (AUZ-454, K03861) is a potent and selective, second-generation inhibitor of mutant FLT3 protein kinase; selectively kills leukemic cells harboring mutant FLT3 with no apparent effect on cells harboring wild-type FLT3, via inhibition of FLT3 kinase activity; potently inhibits cell proliferation of FLT3-ITD-Ba/F3 cells and D835Y-Ba/F3 cells (IC50<1 nM), via induction of apoptosis. ......by ProbeChem
K03861 is a type II CDK2 inhibitor with Kd of 50 nM, 18.6 nM, 15.4 nM, and 9.7 nM for CDK2(WT), CDK2(C118L), CDK2(A144C), and CDK2(C118L/A144C), respectlvely. ......by Selleck Chemicals LLC
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance: EBNumber:EB000022771

Storage condition

Solubility

DMSO: ≥ 33 mg/mL by CHEMSCENE, LLC
DMSO ≥ 33 mg/mL by MedChemexpress Co., Ltd.
5

Mechanism and Indication

Signaling Pathways Cell Cycle/DNA Damage
Target CDK
Research Area Cancer
Indications
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
K03861 - No Development Reported
7

Safety Data of K03861

8

Spectral Information

9

Suppliers List

Company Price and Availability Country/Region
AdooQ BioScience, LLC 5mg/USD150();10mg/USD250();25mg/USD550() USA
Apexbio Technology LLC USA
BOC Sciences 50mg/USD498(In stock)
Biochempartner Co., Ltd China
CHEMSCENE, LLC 2mg/USD120();5mg/USD180() USA
MedChemexpress Co., Ltd. 2mg/USD120();5mg/USD180() USA
MedKoo Biosciences, Inc. USA
ProbeChem
Selleck Chemicals LLC 5mg/USD197();25mg/USD697() USA
Shanghai Haoyuan Chemexpress Co., Ltd. 2mg/USD120();5mg/USD180() China
10

Related Products

Other Forms of 853299-07-7

Name CAS No Formula MW

Recommended Compounds in CDK

Name CAS No Formula MW
LY2857785 1619903-54-6 C26H36N6O 448.6
THZ2 1604810-84-5 C31H28ClN7O2 566.0527
Palbociclib (isethionate) 827022-33-3 C26H35N7O6S 573.66
CDK9-IN-6 1391855-95-0 C27H37ClN6O2 513.07468
ML167 1285702-20-6 C19H17N3O3 335.36
AMG 925 1401033-86-0 C26H29N7O2 471.55
LDC000067 1073485-20-7 C18H18N4O3S 370.43
LEE011 (succinate hydrate) 1374639-79-8 C27H38N8O6X 570.64
LEE011 (succinate) 1374639-75-4 C27H36N8O5 552.63
LEE011 (hydrochloride) 1211443-80-9 C23H31ClN8O 471.0
LEE011 1211441-98-3 C23H30N8O 434.54
WHI-P180 (hydrochloride) 153437-55-9 C16H16ClN3O3 333.77
Wogonin 632-85-9 C16H12O5 284.26
1-NM-PP1 221244-14-0 C20H21N5 331.41
WHI-P180 211555-08-7 C16H15N3O3 297.31
THZ1 1604810-83-4 C31H28ClN7O2 566.05
Senexin A 1366002-50-7 C17H14N4 274.32
CDK4-IN-1 1256963-02-6 C22H29ClN8 440.97
Palbociclib (hydrochloride) 827022-32-2 C24H30ClN7O2 483.99
Purvalanol B 212844-54-7 C20H25ClN6O3 432.9

Recommended Compounds in Same Indication

Name CAS No Formula MW
11

Route of Synthesis

12

References

13

More Information

K03861

Tags: buy 853299-07-7 IC50 | 853299-07-7 price | 853299-07-7 cost | 853299-07-7 solubility | 853299-07-7 purchase | 853299-07-7 manufacturer | 853299-07-7 research buy | 853299-07-7 order | 853299-07-7 MSDS | 853299-07-7 chemical structure | 853299-07-7 Storage condition | 853299-07-7 molecular weight | 853299-07-7 mw | 853299-07-7 datasheet | 853299-07-7 supplier | 853299-07-7 cell line | 853299-07-7 NMR | 853299-07-7 MS | 853299-07-7 IR | 853299-07-7 solubility | 853299-07-7 Safe information | 853299-07-7 Qc and Spectral Information | 853299-07-7 Clinical Information | 853299-07-7 Clinical Trial | 853299-07-7 Route of Synthesis | 853299-07-7 storage condition | 853299-07-7 diseases and conditions | 853299-07-7 flash point | 853299-07-7 boiling point | 853299-07-7 melting point | 853299-07-7 storage condition | 853299-07-7 brand